Form 4: Akari Therapeutics Director Patel Acquires Shares and Options at Nominal Price

Director Samir Rashmikant Patel reports acquisition of Akari Therapeutics shares and options at a price of $0.0006 per share on January 3, 2025.

Summary

• On January 3, 2025, Samir Rashmikant Patel, a director of Akari Therapeutics Plc, acquired 208,000 ordinary shares at $0.0006 per share.
• Patel also acquired stock options for 152,672,000 ordinary shares with an exercise price of $0.000655 per share, exercisable from January 3, 2025, and expiring on January 3, 2035.
• Following the transaction, Patel indirectly owns 5,249,511,500 ordinary shares through PranaBio Investments LLC and directly owns 91,396,000 ordinary shares.
• Patel also directly owns options for 152,672,000 shares.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing, so the sentiment is neutral. It simply reports transactions.

Industry Context

Form 4 filings are standard disclosures required by the SEC to ensure transparency in trading activities by company insiders. This filing indicates changes in the beneficial ownership of Akari Therapeutics' securities by a director.

Stakeholder Impact

• The transaction may have a minor impact on shareholders as it reflects insider activity, but the low share price suggests limited immediate financial implications.

Key Dates